AbbVie shareholder joins the growing ranks of critics, calling for an independent chairman

AbbVie’s $20 billion in revenue from Humira last year has earned high level criticism from US Senators of both parties for a compensation package tied to rising Humira revenue, a long running court battle over the “patent thicket” it’s used to extend its defense against generics until possibly 2023 and now a shareholder flank attack on corporate governance.